



DEVELOPMENT AND CHARACTERIZATION OF
TOPICAL ANALGESIC OINTMENT – FROM
LABORATORY TO PRODUCTION SCALE

BY

NOOR ADIBAH BINTI MD ADIB

A thesis submitted in fulfilment of the requirement for the
degree of Master in Pharmaceutical Sciences
(Pharmaceutical Technology)

Kulliyyah of Pharmacy
International Islamic University Malaysia

DECEMBER 2017

ABSTRACT

The preparation containing methyl salicylate in an ointment dosage form, is available from various manufacturers throughout the world for the treatment of muscular pain. The limitations of the active ingredients had restricted the use of the ointment only for muscular pain. A new combination of methyl salicylate is proposed with other four active pharmaceutical ingredients (API), formulated as an ointment, that is envisaged to give wholesome benefits to the patients as it contained contemporary APIs, combined with natural products. The APIs were methyl salicylates (MS), camphor and menthol, whereas the natural products were eucalyptus oil (EO) and peppermint oil (PO). Peppermint oil contains menthol as one of the components. A proper scale-up of an ointment is very essential due to high variability of characteristics of semisolid formulation from lab scale as compared to production scale. It was also reported that due to the complex nature of the bases present in the combination of some APIs, product stability may suffer. Hence the objectives of this study were to formulate and characterize the analgesic ointment containing five APIs and identifying its critical quality attributes (CQA), to scale-up the formula from lab size to a pilot size, to develop and validate quantitative analytical method quantifying the presence of the APIs from the dosage form, to identify and optimize critical processing parameters (CPP) for the scale-up batches and finally to conduct the accelerated and real-time stability studies for the scale-up batches. Briefly, the lab scale was formulated from 100g to 5kg batch size, consisting of 25% w/w MS, 5% camphor, 5% menthol, 5% EO and 5% PO, by using the overhead stirrer (100 rpm and 15 mins of mixing time). Different formulations were tested by varying the ratio between the two types of ointment bases, namely, petroleum jelly (PJ) and beeswax (BW). It was found that this lab scale gave the pH between 4.83 to 4.93, the hardness between 31.33 to 35.00g, the viscosity between 558 to 2803 mPa.s and the spreadability from 75 to 1947 mPa.s. The ointment exhibited pseudoplastic behaviour with yield stress and was found to be thixotropic. Three formulations consisted of ratios PJ: BW 10:90 (FI), 30:70 (FII) and 50:50 (FIII) were selected to be scaled-up and characterized. The scaled-up was conducted using a vacuum homogenous mixer and automatic tube filling machine for 35kg batch size. It was identified at this stage that the CPPs of vacuum homogeneous mixer were temperature of mixing and cooling, speed of the agitator and the time of mixing. While, CPPs of automatic tube filling machine were dosage and speed. Critical quality attributes (CQA) were identified as physical characteristic, minimum fill, content based on assay and microbial limit test. The formulations FI to FIII were characterized and exhibited pH range from 4.75 to 4.95, viscosity of 735 to 1670 mPa.s and spreadability of 735 to 1670 mPa.s. The ointment exhibited pseudoplastic behaviour with yield stress and found to be thixotropic. By using gas chromatography coupled with flame iodide detector (GC-FID), analytical method was developed and validated using the scale-up batches and all parameters namely specificity, limit of quantification (LOQ), linearity and range, precision and recovery, and intermediate precision fulfil the specification. After storage up to 6 months, the percentage content of MS, camphor, menthol, EO and PO were 24.6 to 25.9% w/w, 4.6 to 4.8% w/w, 6.8 to 7.5% w/w, 4.95 to 5.2% w/w and 6.85 to 7.1% w/w respectively. Hence, we conclude that a stable ointment consisted of five APIs had been successfully formulated and scaled-up. The predicted shelf life was 2.1 years.

خلاصة البحث

المستحضرات المحتوية على ساليسيلات الميثيل على شكل مرهم متاح من قبل مختلف الشركات المصنعة في جميع أنحاء العالم لعلاج آلام العضلات. قيدت محدودية المكونات النشطة استخدام المراهم فقط لآلام العضلات. اقترحت في هذه الدراسة تركيبات جديدة لساليسيلات الميثيل مع أربعة مكونات صيدلانية نشطة (API)، محضرة كمرهم، والتي من المتوقع أن تعطي فوائد صحية للمرضى لاحتوائها على مكونات صيدلانية نشطة حديثة بالإضافة إلى مركبات طبيعية. المكونات الصيدلانية النشطة كانت ساليسيلات الميثيل، والكافور، والمنثول، والمركبات الطبيعية كانت زيت الكافور، وزيت النعناع. يضمن زيت النعناع المنثول كأحد المكونات. تضخيم إنتاج المرهم أمر ضروري بسبب التباين الكبير في خصائص المستحضرات الشبه الصلبة المصنعة مخبريا مقارنة بالإنتاج الصناعي. أكدت التقارير أيضا أنه نظرا للطبيعة المعقدة للقلويات الموجودة في بعض التركيبات للمكونات الصيدلانية النشطة فاستقرار المنتج قد يتأثر. وللك كله هدفت هذه الدراسة لصياغة وتوصيف مرهم مسكن يحتوي على خمسة مكونات صيدلانية نشطة، وتحديد سمات الجودة الهامة الخاصة بها (CQA)، لتضخيم نطاق المستحضر من الحجم المخبري إلى الحجم التجريبي، وللتطوير والتحقق من صحة طريقة التحليل الكمي لتحليل وجود مكونات صيدلانية نشطة من الشكل الجرعي، ولتحديد وتحسين معايير المعالجة الهامة (CCP) لدفعات التضخيم، وأخيرا هدفت الدراسة لإجراء دراسات الاستقرار المتسارعة والحالية لدفعات التضخيم. باختصار، تم اعداد المستحضر مخبريا من حجم 100 غ إلى 5 كغ لحجم الدفعة والتي تألفت من 25% سائل/سائل ساليسيلات الميثيل، 5% من الكافور، 5% من المنثول، 5% من زيت النعناع، و5% من زيت الأوكالبتوس باستخدام القلاب العلوي (100 دورة في الدقيقة و 15 دقيقة من وقت الخلط). تم اختبار تركيبات مختلفة من خلال تغيير النسبة بين نوعي المادة الأساسية للمرهم، وهما الهلام النفطي وشمع العسل. وجد أن المستحضر المعد مخبريا أعطى مستوى حموضة بين 4.83 إلى 4.93، وصلابة بين 31.33 إلى 35.00 g، ولزوجة بين 558 إلى 2803 مل باسكال، وانتشار من 75 إلى 1947 مل باسكال. أظهر المرهم سلوكا شبه لدني مع مع تأثير على التحصيل وكان متميعا بالهز. تم اخيار ثلاثة تركيبات بالنسب الآتية: شمع العسل والهلام النفطي (FI) 10:90، (FII) 30:70 و (FIII) 50:50 لتضخيم انتاجها وبعد ذلك تصنيفها. تم إجراء هذا التضخيم باستخدام خلاط مشفط متجانس وآلة ملء أنبوب تلقائية لدفعة ذات حجم 35 كجم. تم التعرف في هذه المرحلة على أن معايير المعالجة الهامة للخلاط المشفط المتجانس كانت درجة حرارة الخلط والتبريد، وسرعة الهزاز، ومدة الخلط. بينما معايير المعالجة الهامة لكبس أنابيب الملء التلقائية كانت كمية الجرعة والسرعة. تم تحديد سمات الجودة الهامة (CQA) بالخصائص الفيزيائية، والحد الأدنى للملء، المحتوى المعتمد على الفحص واختبار الحد الميكروبي. اتسمت تركيبات FI و FII وأظهرت درجة حموضة تراوحت من 4.75 إلى 4.95، ولزوجة من 735 إلى 1670 مل باسكال، وانتشار من 735 إلى 1670 مل باسكال. أظهر المرهم سلوكا شبه لدني مع تأثير على الإنتاج وكان متميعا بالهز. تم تطوير الطريقة التحليلية والتحقق من صحتها باستخدام الكروماتوغرافيا للغازية مع كاشف لهب الأيوديد (GC-FID) مع دفعات الإنتاج المضخمة وكانت جميع المعلمات وهي التحديد، وحد التحديد الكمي (LOQ)، والخطية والمدى، والدقة والاسترداد، والدقة الوسطية مستوفية للمواصفات. بعد التخزين لمدة وصلت إلى 6 أشهر، كانت نسبة محتوى ساليسيلات الميثيل 24.6 – 25.9% و/و، والكافور 4.6 – 4.8% و/و، والمنثول 6.8 – 7.5% و/و، زيت النعناع 4.95 – 5.2% و/و، وزيت الأوكالبتوس 6.85 – 7.1% و/و. وختاما استنتج أن مرهما مستقرا يتألف من خمسة مكونات صيدلانية نشطة قد تمت صياغته وتضخيم انتاجه بنجاح، وكانت مدة صلاحيته المتوقعة حوالي 2.1 سنة.

APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion, it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Bappaditya Chatterjee
Supervisor

.....
Farahidah Mohamed
Co-Supervisor

.....
Uttam Kumar Mandal
Co-Supervisor

I certify that I have read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Kausar Ahmad
Internal Examiner

.....
Haliza Katas
External Examiner

This thesis was submitted to the Department of Pharmaceutical Technology and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Mohd Rushdi bin Haji Abu Bakar
Head, Department of
Pharmaceutical Technology

This thesis was submitted to the Kulliyah of Pharmacy and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Juliana Md. Jaffri
Dean, Kulliyah of Pharmacy

DECLARATION

I hereby declare that this dissertation is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Noor Adibah Binti Md Adib

Signature..... Date.....

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**DEVELOPMENT AND CHARACTERIZATION OF TOPICAL
ANALGESIC OINTMENT – FROM LABORATORY TO
PRODUCTION SCALE**

I declare that the copyright holders of this dissertation are jointly owned by the student and IIUM.

Copyright © 2017 Noor Adibah Binti Md Adib and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Noor Adibah Binti Md Adib

.....
Signature

.....
Date

ACKNOWLEDGEMENTS

All thanks and praises to Allah, The Almighty for granting me life, good health and strength. Without His Will, I would not be able to complete my thesis successfully. This thesis represents the results of many experiences I have encountered at Kulliyyah of Pharmacy from dozens of remarkable individuals. I would like to offer my sincere thanks to all people that were involved in my research directly and indirectly, who enabled me to obtain quality data needed for my research. May Allah bless all of you till Jannah.

First and foremost, it is my utmost pleasure to dedicate this work and warmly thank and appreciate my husband, Muhammad Subri Bin Manaf, my daughter, Aisyah Damia and Sakinah Zinnirah, my son, Izz Emir Al-Furqan, who granted me the gift of their unwavering belief in my ability to accomplish this goal, thank you for your support and patience. To my dear parents, Hj Md Adib and Hjh Norsiah thanks to both of you for their material and spiritual support in all my life. To my dear father in-law and mother in-law, Manaf and Siti Fatimah thanks to both of you for their spiritual support during preparation of my thesis. I also would like to thank my sisters (Nor Ain and Nurul Nazirah) and brother (Mohd Nor Azra and Mohd Nor Salleh), they have aided in numerous ways. May Allah give you all the best in return.

I am most indebted to my supervisor, Asst. Prof. Dr. Bappaditya Chatterjee, whose enduring disposition, kindness, promptitude, thoroughness and friendship have facilitated the successful completion of my work. I put on record and appreciate his detailed comments, useful suggestions and inspiring queries which have considerably improved this thesis. His brilliant grasp of the aim and content of this work led to his insightful comments, suggestions and queries which helped me a great deal. Despite his commitments, he took time to listen and attend to me whenever requested. The moral support he extended to me is in no doubt a boost that helped in building and writing the draft of this research work. I am also grateful to my co-supervisor, Assoc. Prof. Dr. Farahidah Binti Mohamed, to be a true mentor, sometimes leading, sometimes showing me the way, at other time giving me the freedom to explore, but always available with wisdom, advise and support. I would also like to express my gratitude to my co-supervisor, Asst. Prof. Dr. Uttam Kumar Mandal for his support, understanding and guidance into the world of research. Thank you for sharing your knowledge and experience.

I wish to express my appreciation and thanks to those who provided their time, effort and support for this project. To the members of my thesis committee, thank you for sticking with me.

May Allah grant us all success in the world and in the hereafter, amin.

TABLE OF CONTENTS

Abstract	ii
Abstract in Arabic	iii
Approval page	iv
Declaration	vi
Copyright Page.....	vii
Acknowledgements	viii
Table of Contents	ix
List of Tables	xi
List of Figures	xiv
List of Equations	xvi
List of Symbols	xvii
List of Abbreviations	xviii
CHAPTER ONE: INTRODUCTION	1
1.1 Background of The Study	1
1.2 Problem Statement.....	2
1.3 Research Objectives.....	3
CHAPTER TWO: LITERATURE REVIEW	4
2.1 Pain	4
2.1.1 Definition of Pain.....	4
2.1.2 Types of Pain	4
2.1.3 Management of Pain	5
2.2 Analgesics.....	6
2.2.1 Systemic Analgesic	6
2.2.2 Transdermal Analgesic	7
2.2.3 Topical Analgesic	7
2.3 Topical Dosage Form	8
2.3.1 Topical Analgesic Ointment	9
2.3.2 Drawback of Topical Analgesic Ointment.....	11
2.4 Active Pharmaceutical Ingredients	11
2.4.1 Methyl Salicylate	11
2.4.2 Camphor	14
2.4.3 Menthol and Peppermint Oil.....	15
2.4.4 Eucalyptus Oil.....	19
2.4.5 Combination of API.....	20
2.5 Formulation of Analgesic Ointment	22
2.5.1 Formulation Principle	22
2.5.2 Selection of Permitted Level and Combination	23
2.6 Characterization.....	27
2.6.1 Quantitative Analysis of The Ingredients By GC-FID Methods ..	27
CHAPTER THREE: RESEARCH METHODOLOGY	30
3.1 Materials/Apparatus/ Equipment/Chemicals	30
3.2 Methods	32

3.2.1 Pre-Formulation Studies	32
3.2.2 Formulation	32
3.2.3 Characterization of Laboratory Scale Trial Batches	34
3.2.4 Testing CQA for The Ointment	37
3.2.5 Scale-Up	37
3.2.6 Characterization of Scale-Up Batches	39
3.2.7 Critical Processing Parameter (CPP)	40
3.2.8 Development of Analytical Method for Estimation of Methyl Salicylate, Camphor, Menthol, Eucalyptus Oil, and Peppermint Oil.....	41
3.2.9 Analytical Method Validation (AMV).....	43
3.2.10 Stability Study.....	51
CHAPTER FOUR: PRESENTATION OF RESULTS AND DISCUSSION...53	
4.1 Pre-Formulation Studies	53
4.1.1 Physical Characterization.....	53
4.1.2 Drug-Excipients Compatibility Study by ATR-FTIR.....	54
4.2 Formulation and Characterization of Laboratory Scale Trial Batches ...	60
4.2.1 Phase Separation	60
4.2.2 pH.....	60
4.2.3 Hardness	60
4.2.4 Rheological Parameters (Viscosity, Spreadability, Yield Stress, and Thixotropy).....	62
4.2.5 CQAs of The Ointment Derived by The Lab Scale Formulation	63
4.3 Scale-Up and Characterization of Scale-Up Batches	63
4.3.1 Characterization of Scale-Up Batches	65
4.3.2 CPP Derived by The Scale-Up Batches	69
4.3.3 CQA of Ointment Derived by The Scale-Up Batches	72
4.4 Development and Validation of Analytical Method.....	73
4.4.1 Analytical Method Validation.....	73
4.5 Stability Study	83
4.5.1 Characterization for Stability Studies of Ointments	83
4.5.2 Physical Stability.....	83
4.5.3 Chemical Stability.....	83
CHAPTER FIVE: CONCLUSION	96
REFERENCES.....	99
APPENDIX I: LIST OF CONFERENCE PROCEEDINGS AND PUBLICATIONS	111
APPENDIX II: ABSTRACT APPEARED IN THE ABSTRACT BOOK OF ICIP 2016 – 2ND INTERNATIONAL CONFERENCE ON INDUSTRIAL PHARMACY, KUANTAN, PAHANG, MALAYSIA	112
APPENDIX III: PUBLICATIONS APPEARED IN THE JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2017.....	113

LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
2.1	Methyl salicylate as sole counterirritant in some commercial products	13
2.2	Camphor as sole counterirritant in some commercial products	15
2.3	Menthol as sole counterirritant in some commercial product	18
2.4	External analgesic commercial product containing methyl salicylate, camphor, menthol, eucalyptus oil and peppermint oil as API	21
2.5	Permitted combinations of API and their effects	24
2.6	Dose limitation of each Active Pharmaceutical Ingredient (API)	24
2.7	Combination of APIs between groups	25
2.8	Monographs published in the British (BP), European (EP), and American (USP) Pharmacopoeias	26
3.1	Raw Materials	30
3.2	Reference Standard	30
3.3	Apparatus and equipment	31
3.4	Combined base formulation	33
3.5	Composition of trial formulations	33
3.6	Process parameter during lab scale	34
3.7	Base formulation A to C	38
3.8	Formulation code	38
3.9	Process parameter for scale-up use homogenize mixer	40
3.10	Process parameter for scale-up trial using automatic tube filling machine	41
3.11	GC-FID conditions fixed for analysis	43
3.12	Concentration of reference standard stock and mix standard solution	45
3.13	Concentration of sample stock and sample solution for each raw material inside ointment	46

3.14	System suitability parameters for the developed GC method with acceptable values	47
3.15	Stability study sampling time points and condition	52
4.1	Physical characteristics of the ointment raw materials	53
4.2	Summary of the initial characterization for Formulation I to VI laboratory scale batch (values are mean \pm SD, n = 3)	61
4.3	CQA of analgesic ointment	63
4.4	Monitoring temperature during SC01	64
4.5	Summary of initial characterization for composition SC 01 to SC 03 scale-up batches (values are mean \pm SD, n = 3)	68
4.6	Specification of content of each active (%)	69
4.7	Percentage content of each active	69
4.8	CPP during manufacturing process of ointment	71
4.9	CQA of analgesic ointment derived from scale up batches	72
4.10	System suitability parameters derived from the developed GC method	74
4.11	Predicted and confirmed values of LOQ (QL) of four analytes obtained by the GC method	75
4.12	Linearity value of individual analyte derived by developed GC method	77
4.13	Concentration used in linearity study	77
4.14	Precision Percent recovery (accuracy) – precision values of individual analyte derived by GC method	79
4.15	Degradation of methyl salicylate in ointment prepared from base petroleum jelly and beeswax (50:50) containing 25% w/w methyl salicylate, 5% w/w camphor, 5% w/w menthol, 5% w/w eucalyptus oil, and 5% w/w peppermint oil stored inside aluminium collapsible tubes	84
4.16	Degradation of camphor in ointment prepared from base petroleum jelly and beeswax (50:50) containing 25% w/w methyl salicylate, 5% w/w camphor, 5% w/w menthol, 5% w/w eucalyptus oil, and 5% w/w peppermint oil stored inside aluminium collapsible tubes	84
4.17	Degradation of menthol in ointment prepared from base petroleum jelly and beeswax (50:50) containing 25% w/w methyl salicylate, 5% w/w camphor, 5% w/w menthol, 5% w/w eucalyptus oil, and 5% w/w peppermint oil stored inside aluminium collapsible tubes	85

4.18	Degradation of eucalyptus oil in ointment prepared from base petroleum jelly and beeswax (50:50) 25% w/w methyl salicylate, 5% w/w camphor, 5% w/w menthol, 5% w/w eucalyptus oil, and 5% w/w peppermint oil stored inside aluminium collapsible tubes	85
4.19	Degradation of peppermint oil in ointment prepared from base petroleum jelly and beeswax (50:50) containing 25% w/w methyl salicylate, 5% w/w camphor, 5% w/w menthol, 5% w/w eucalyptus oil, and 5% w/w peppermint oil stored inside aluminium collapsible tubes	86
4.20	Parameters for calculation of shelf-life of each active (a) methyl salicylate, (b) camphor, (c) menthol, (d) eucalyptus oil, and (e) peppermint oil inside ointment inside aluminium collapsible tubes	91

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
2.1	Chemical structure of methyl salicylate	11
2.2	Chemical structure of camphor	14
2.3	Chemical structure of menthol	16
2.4	Chemical structure of eucalyptol	19
3.1	Texture analyser with the cylinder probe attached	35
3.2	Texture analyser with male cone probe attached	36
4.1	IR Spectra of (a) synthetic beeswax 1540 and (b) white petroleum jelly	54
4.2	IR Spectra of all APIs; (a) methyl salicylate, (b) camphor powder, (c) menthol crystal, (d) eucalyptus oil, and (e) peppermint oil 50%	57
4.3	IR Spectra of analgesic ointment containing all raw materials	59
4.4	Forward and backward rheogram (thixotropic loop) for lab scale batch	62
4.5	Forward and backward rheogram (Thixotropic loop) for scale-up batches of base	67
4.6	Forward and backward rheogram (Thixotropic loop) for scale-up batches of analgesic ointment (base and API)	67
4.7	Representative chromatogram of 50% spiked sample of camphor, menthol, and methyl salicylate (accuracy-precision study)	80
4.8	Representative chromatogram of 100% spiked sample of camphor, menthol, and methyl salicylate (accuracy-precision study)	80
4.9	Representative chromatogram of 150% spiked sample of camphor, menthol, and methyl salicylate (accuracy-precision study)	81
4.10	Representative chromatogram of 50% spiked sample of eucalyptus oil (accuracy precision study)	81
4.11	Representative chromatogram of 100% spiked sample of eucalyptus oil (accuracy-precision study)	82

4.12	Representative chromatogram of 150% spiked sample of eucalyptus oil (accuracy-precision study)	82
4.13	First order degradation kinetics of (a) methyl salicylate, (b) camphor, (c) menthol, (d) eucalyptus oil, and (e) peppermint oil in ointment stored in aluminium collapsible tubes at different temperatures	89
4.14	Arrhenius plot for optimized (a) methyl salicylate, (b) camphor, (c) menthol, (d) eucalyptus oil, (e) peppermint oil in ointment	94

LIST OF EQUATIONS

Resolution between an analyte peak and its preceding peak (R_s)

$$R_s = \frac{2(T_{R1} - T_{R2})}{(W_1 + W_2)}$$

Number of theoretical plate (N)

$$N = 16 \left(\frac{T_R}{W} \right)^2$$

Retention factor (K')

$$K' = \frac{(T_R - T_0)}{T_0}$$

Tailing factor (T)

$$T = \frac{W_{5.0}}{T_w \cdot 2}$$

Reproducibility of peak area response (% RSD) where $n = 6$

$$\% \text{ RSD} = \frac{SD_{area}}{Mean_{area}} \times 100$$

Limit of Quantitation (LOQ)

$$LOQ = \frac{10 \sigma}{S}$$

% Recovery

$$\frac{\text{Amount recovered (ppm)}}{\text{Amount added (ppm)}} \times 100$$

First order reaction rate constant (K) per month for each temperature

$$\text{Slope} = \frac{-K}{2.303}$$

Value of K at 25°C (K_{25}) was extrapolated from the Arrhenius plot and shelf life of the formulation was calculated by substituting the value of K_{25}

$$t_{90} = 0.1054/k_{25}$$

LIST OF SYMBOLS

$^{\circ}\text{C}$	degree Celsius
cm^{-1}	per centimetre
G	Gram
g/mol	Gram per mol
Hz	Hertz
Kg	Kilogram
mg/kg	Milligram per kilogram
mPa.s	milipascal second
s^{-1}	per second

LIST OF ABBREVIATIONS

ALS	Automatic liquid sampler
API	Active pharmaceutical ingredient
ATR-FTIR	Attenuated reflectance infra-red spectroscopy
BP	British Pharmacopoeia
BW	Beeswax
CNS	Central nervous system
CPP	Critical processing parameter
CQA	Critical quality attribute
EO	Eucalyptus oil
EP	European Pharmacopoeia
FDA/USFDA	The Food and Drug Administration is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments.
FI	Formulation I
FII	Formulation II
FIII	Formulation III
French BIAM	Short form for Banque des Données Automatisées sur les Médicaments (word in French). One of the French data bases specialised in the cataloguing of drugs and substances that are created between French universities and the pharmaceutical industries and is used by pharmaceutical laboratories.
GC-FID	Gas chromatography coupled with flame ionization detector
GI	Gastrointestinal
GMP	Good Manufacturing Practice guideline
ICH	International Conference on Harmonization of Technical Requirements for Registration on Pharmaceuticals for Human Use
ICH Q2 (R1)	International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) Validation of

	Analytical Procedure
IM	Intramuscular
IR spectra	Infrared spectra
IS	Internal standard
IUPAC	International Union of Pure and Applied Chemistry
IV	Intravenous
LC	Liquid chromatography
LOD	Limit of detection
LOQ	Limit of quantitation
MS	Methyl salicylate
NPRA	National Pharmaceutical Regulatory Agency in Malaysia
NSAIDs	Nonsteroidal anti-inflammatory drug
o/w	Oil-in-water
OTC	Over-the-counter
PEG	Polyethylene glycol polymer
PJ	Petroleum jelly
PO	Peppermint oil
SHS-GC	Static headspace-gas chromatography
SST	System suitability test
TGA	Australian Therapeutic Goods Administration
USA	United States of America
USP	United States Pharmacopoeia
w/o	Water-in-oil
WHO	World Health Organization

CHAPTER ONE

INTRODUCTION

1.1 BACKGROUND OF THE STUDY

Pain is a condition that is experienced by human in any stage of life that gives stress to the sensory and an uncomfortable feeling to the body with possible tissue harm. It is not only a sensation, but it is an indication of a disease. According to the World Health Organization (WHO), it is an unpleasant sensory and emotional experience. The pain can be a warning signal, when the body has been damaged. In the lives of human, it plays an important role. The pain serves to protect us from harm and to alert us to diseases or conditions. Even though not all pains need treatment, the pains need to be attended to, in order to treat the actual diseases. Therefore, the management of pain is important to give relieve to the patient.

The pain can be managed by some medication as well as some supportive therapy. These medications can be a modern or a traditional one. The established medication or analgesics include ibuprofen and acetaminophen. The traditional management of pain include application of herbal medicines containing extracts, derived from parts of the plants or other plant materials as active ingredients. The supportive therapies include meditation, heat and cold therapy, massage, and relaxation technique. In addition, topical analgesic is one of the most common ways to get immediate relief from pain. There are a variety of topically available active pharmaceutical ingredients (API) which are formulated as ointment, cream, or spray. They include diclofenac sodium, menthol. and methyl salicylate.

According to Medical Dictionary for the Health Professions and Nursing (2012), the topical analgesic is a compound that can produce analgesia which acts as

pain-relieving drug without causing unconsciousness. One of the characteristics of these topical analgesics is responding to reduction of painful stimulation. Camphor, menthol, methyl salicylate, eucalyptus oil, and peppermint oil are some popularly known and well-established APIs for topical ointment.

The formulation of an ointment varies greatly from lab scale to large scale because of the possible variation process parameter due to the difference in the equipment. During the initial study, lab scale formula was applied to identify the critical quality attributes (CQAs) and during the initial scale-up, critical processing parameters (CPP) were identified. These two factors were essential to ensure appropriate manufacturing scale to be developed and to fulfil regulatory requirement.

1.2 PROBLEM STATEMENT

Methyl salicylates (MS), camphor, menthol, eucalyptus oil (EO) and peppermint oil (PO) are commonly used ingredients in analgesic ointment. These ointments are used separately or combined as two to three ingredients of an ointment. However, till date, to the best of our knowledge, there is no such ointment that combines all these five ingredients together in one dosage form. There are high variability of characteristics of semisolid formulation prepared from lab scale to large scale. Proper scale-up of ointment is very essential in this respect. But there is not much work published on the scale-up considerations of ointment although it is a very common dosage form, perhaps owing to the trade secret. Combination of ingredients might lead to the difficulty in finding suitable formulation to ensure product stability, especially for semisolids due to the complex nature of the bases used. Therefore, imparting stability to the ointment containing large number of APIs is one of the major associated problems.

1.3 RESEARCH OBJECTIVES

The main aim of the research was to formulate and scale up an analgesic ointment containing camphor, menthol, methyl salicylate, eucalyptus oil and peppermint oil to produce it at commercial scale. To achieve this, the research was targeted to the fulfilment of the following objectives:

- 1- To formulate five APIs combination and characterize the ointment by identifying its CQA.
- 2- To scale up the ointment while identifying its CPP.
- 3- To develop and validate the analytical method to quantitatively analyse the five APIs using Gas Chromatography-Flame Ionisation Detector (GC-FID).
- 4- To carry out the stability study of the developed and scaled-up ointment according to the ICH guidelines (ICH Q1A to ICH Q1F).

CHAPTER TWO

LITERATURE REVIEW

2.1 PAIN

2.1.1 Definition of Pain

Pain often refers to unpleasantness and discomfort or any negative emotion and negative effect of a sensory experience. It can range from mild to extreme level. Pain can probably be resulting from an actual tissue damage to body or can occur even in the absence of any physical harm. Pain can be influenced by a various source variability that comes from nurture (environment) and nature (genes). Environmental factors include psychological and personality related factors such as previous pain experience, emotionality, anxiety, and fear. Molecular genetic of pain includes the identified genetic risk factors contributing to the pain in human (Atlas & Wager, 2012; Belfer, 2013; National Institutes of Health [NIH], 2011).

2.1.2 Types of pain

One of the common classifications of pain is based on duration. It can distinguish pain into categories called acute and chronic pains. Acute pain lasts for a short time. The time frame is less than three months and maybe as brief as seconds (Radnovich et al., 2014). These include post-operative pain which requires only short-term care. Chronic pain, in contrast, lasts beyond the healing of an injury and can continue for a period of more than three months. It lasts longer due to the nature and symptoms of disease that requires multi-therapeutic activities and long term care management (Koneti & Jones, 2013; Radnovich et al., 2014; Swieboda, Filip, Prystupa, & Drozd, 2013).

2.1.3 Management of pain

Pain needs to be controlled as it can affect the quality of life. If pain is not treated, it can affect the individual's sleep and decrease appetite. The comprehensive pain managements generally include pharmacologic intervention and non-pharmacologic intervention. Pharmacologic intervention is also known as pharmacologic therapy which is a type of medical care that involves medication either alone or in combination with other types of therapy. There is an alternative way to control pain without the use of medicines, which is known as non-pharmacologic therapy or non-pharmacologic intervention. This may include changes in life-style such as diet, exercise and control of smoking and alcohol consumption.

Pharmacologic therapies involve several classes of drug. The three categories that treat pain are acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids. For neurological pain, pharmacological intervention includes anticonvulsant and gabapentin as recommended by WHO (Keskinbora, Pekel, & Aydinli, 2007). But for severe neuropathic pain, local anaesthetics such as transdermal lignocaine and oral lignocaine analogue, Mexiletine is given to relieve the pain (Clancy, 2012). In addition, adjuvants may also be prescribed, those include muscle relaxants and anticonvulsants (Nalamachu, 2013). Breast cancer patients receiving chemotherapy usually have problems with cognitive alterations. These patients receive pharmacologic interventions including psychostimulants, epoetin alfa, and ginkgo biloba (Chan, McCarthy, Devenish, Sullivan, & Chan, 2015).

Generally, the non-pharmacological treatment that is used to control the pain includes application of heat, ice, massage, and physical therapies. In addition, aroma therapy, guided imagery, laughter, music, self-hypnosis, and acupuncture are commonly used. The types of non-pharmacological treatment methods, used to relieve